Maricann Group (CNSX:MARI – Get Free Report) had its target price boosted by equities research analysts at National Bankshares from $13.25 to $15.00 in a research report issued to clients and investors on Thursday,BayStreet.CA reports.
Separately, Royal Bank Of Canada increased their price objective on shares of Maricann Group from $6.00 to $16.00 in a report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $14.10.
Check Out Our Latest Research Report on MARI
Maricann Group Price Performance
About Maricann Group
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients. The Company is undertaking an expansion of the cultivation and support facilities to support existing and future patient growth.
Recommended Stories
- Five stocks we like better than Maricann Group
- Do not delete, read immediately
- Refund From 1933: Trump’s Reset May Create Instant Wealth
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.
